FDA to Review 7 Peptides for Compounding List in July 2026: BPC-157, Semax, Epitalon, and More
The Food and Drug Administration has scheduled a two-day public meeting in July 2026 to review seven peptides that patients, clinicians, and compounding pharmacies have been watching closely. The meeting could open a clearer legal path for pharmacies to compound these substances for patient-specific prescriptions. Today we break down what was announced, which peptides are on the agenda, and what the regulatory pathway actually means.
Interested in peptide therapy? Find vetted peptide therapy clinics near you.
| Key Detail | Summary |
|---|---|
| What happened | FDA filed Federal Register notice scheduling a Pharmacy Compounding Advisory Committee (PCAC) meeting |
| Meeting dates | July 23 and 24, 2026 at FDA White Oak Campus in Silver Spring, MD |
| Peptides under review | BPC-157, KPV, TB-500, MOTS-C, Emideltide (DSIP), Semax, Epitalon |
| Regulatory action | Considered for inclusion on the Section 503A Bulk Drug Substances List |
| Public comment deadline | July 9, 2026 to be reviewed by the Committee; docket closes July 22, 2026 |
| Federal Register doc | FR Doc. 2026-07361, Docket No. FDA-2025-N-6895 |
What the FDA Actually Announced
On April 15, 2026, the FDA filed a notice in the Federal Register announcing a meeting of the Pharmacy Compounding Advisory Committee. The Committee provides advice and recommendations to the agency on regulatory issues related to drug compounding. The full notice is available at federalregister.gov. The meeting is scheduled for July 23 and 24, 2026 and will be open to the public both in person and through an online teleconferencing platform.
The Committee will review whether seven peptides should be added to the Section 503A Bulk Drug Substances List. That list controls which raw drug substances licensed pharmacists and physicians can legally use to compound medications for individual patients. If a substance is not on the list, does not have a U.S. Pharmacopoeia monograph, and is not a component of an FDA-approved drug, compounding it under Section 503A is not permitted.
The 7 Peptides Under Review
The FDA has split the review across two days. On July 23, 2026 the Committee will discuss four peptides. On July 24, 2026 the Committee will discuss three more. Each peptide is being evaluated for a specific therapeutic use, which the FDA identified in the Federal Register notice.
Day One (July 23, 2026)
| Peptide | Use Being Evaluated |
|---|---|
| BPC-157 (free base and acetate) | Ulcerative colitis |
| KPV (free base and acetate) | Wound healing and inflammatory conditions |
| TB-500 (free base and acetate) | Wound healing |
| MOTS-C (free base and acetate) | Obesity and osteoporosis |
Day Two (July 24, 2026)
| Peptide | Use Being Evaluated |
|---|---|
| Emideltide (also known as DSIP) | Opioid withdrawal, chronic insomnia, narcolepsy |
| Semax (free base and acetate) | Cerebral ischemia, migraine, trigeminal neuralgia |
| Epitalon (free base and acetate) | Insomnia |
Nominators of each substance will be invited to make short presentations in support of their nomination. The public will also have time to submit oral and written comments. The FDA has allotted roughly one hour per meeting day for open public hearing presentations.
Understanding the 503A Bulks List
Section 503A of the Federal Food, Drug, and Cosmetic Act sets the conditions that must be met for a compounded drug product to be exempt from three key federal requirements: current good manufacturing practice standards, labeling with adequate directions for use, and approval under a new drug application. A licensed pharmacist or physician can compound a drug product under Section 503A only if the bulk drug substance meets one of three criteria. It must comply with an applicable U.S. Pharmacopoeia or National Formulary monograph. Or it must be a component of an FDA-approved drug. Or it must appear on the 503A Bulks List maintained by the Secretary of Health and Human Services.
For peptides like BPC-157 and Semax, none of the first two conditions apply. There is no USP monograph. There is no FDA-approved drug that contains them. That leaves the 503A Bulks List as the only legal pathway for compounding pharmacies to work with these substances. If PCAC recommends a peptide for inclusion and the FDA ultimately adds it, compounding becomes lawful under Section 503A. If not, the substance remains outside the compounding framework.
Find verified providers in our BPC-157 & recovery peptide clinic directory.
Why This Matters for Patients and Clinicians
The peptides on this agenda have developed substantial patient interest over the past several years. BPC-157 has been studied for gastrointestinal and tendon injury applications. Semax has a long history of use outside the United States for neurological and cognitive conditions. Epitalon has been researched for sleep and aging-related outcomes. MOTS-C has drawn attention for potential metabolic and bone health benefits. For a deeper dive on how peptides work and the broader landscape, see our guide to peptide therapy.
Until now, patients seeking these peptides have had limited legal options. Many have turned to gray-market online sellers labeling products as “research chemicals.” Those products carry real safety risks: unknown purity, no sterility guarantees, and no oversight on dosing. A path through the 503A Bulks List would change that. Patients would be able to get prescriptions filled at licensed compounding pharmacies under physician supervision. For clinicians, that means clearer legal footing and better documentation for patient records.
What PCAC Actually Does
PCAC is an advisory committee. Its job is to review the scientific evidence and make recommendations to the FDA. The committee examines whether a substance is eligible for inclusion on the 503A Bulks List. The analysis typically considers four factors: the physical and chemical characterization of the substance, any safety issues raised by using the substance in compounding, the available evidence of effectiveness for the use, and historical use of the substance in compounding, including the medical condition being treated and any references in the medical literature.
Recommendations are non-binding. The FDA ultimately decides whether to add a substance to the list. But PCAC recommendations carry significant weight. A positive recommendation tends to move the process forward. A negative one often means the substance stays off the list.
How the Public Can Participate
The FDA has established a public docket under Docket No. FDA-2025-N-6895 to receive comments. Anyone can submit written comments electronically through regulations.gov or by mail. Comments received on or before July 9, 2026 will be provided to the Committee in advance of the meeting. The docket stays open until July 22, 2026. Late comments will not be considered. Individuals who want to make oral presentations at the meeting must notify the FDA contact person by June 30, 2026.
For press inquiries about the meeting, the FDA directs reporters to the HHS Press Room. The technical contact for the docket is Takyiah Stevenson at the Center for Drug Evaluation and Research, reachable at [email protected] or 240-402-2507.
What Happens Next
Each of the seven peptides now sits in front of a formal scientific review by PCAC. The committee will hear presentations from the nominators, evaluate the background materials the FDA posts two business days before the meeting, and vote on recommendations. Patients and clinicians who want to weigh in have until July 9, 2026 to submit comments that the committee will see directly.
We will cover the outcomes here at HealingMaps as soon as the meeting concludes. If you are looking for a clinician working with any of these peptides today, our peptide therapy directory lists verified practitioners across the country.
Sources
This article is based on the Federal Register notice FR Doc. 2026-07361, filed April 15, 2026 and scheduled for publication on April 16, 2026. Signed by Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs, FDA. Section 503A of the Federal Food, Drug, and Cosmetic Act is codified at 21 U.S.C. 353a.
